Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Silence Therapeutics plc

Silence Therapeutics plc (SLN) Stock Overview

Explore Silence Therapeutics plc’s financial performance, market position, analyst ratings, and future outlook.

SLN●NASDAQ
HealthcareBiotechnology
$19.58
$10.90(125.58%)
U.S. Market opens in 16h 43m

Silence Therapeutics plc (SLN)

Meyka AI Score

Z

Key Financials

Market Cap924.6M
P/E Ratio-2.31
EPS (TTM)$-1.28
ROE-1.07%
Fundamental Analysis

AI Price Forecasts

1 Month$10.85
3 Months$12.31
1 Year Target$8.22

SLN Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Silence Therapeutics plc (NASDAQ: SLN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Silence Therapeutics plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of SLN on the NASDAQ shows an RSI of 26.15, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $8.22 for the NASDAQ listing.

Key metrics behind Silence Therapeutics plc's NASDAQ-traded stock include a P/E ratio of -2.31 and a market capitalization of 924.6M. Combined with our AI analysis, these give both institutional and retail investors a clear view of SLN on the NASDAQ.

Price Performance (NASDAQ: SLN)

1-Day Change
125.58%
5-Day Change
119.75%
1-Month Change
60.49%
3-Month Change
86.48%
6-Month Change
160.03%
Year-to-Date (YTD) Change
222.04%
1-Year Change
172.32%
3-Year Change
165.31%
5-Year Change
-7.12%
All-Time (Max) Change
0.41%

Contact Information

https://www.silence-therapeutics.com
44 20 3457 6900
72 Hammersmith Road, London, GL, W6 7AP

Company Facts

880 Employees
IPO DateSep 8, 2020
CountryGB
Actively Trading

Frequently Asked Questions